5 completed, 3 recruiting, 2 active not recruiting, 2 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Active not recruiting 1, Completed 1, Not yet recruiting 1 |
Follow Adaptive Biotechnologies: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP Mosunetuzumab, ClonoSEQ - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Danielle Wallace | 40 | 2025-09-04 | 2025-10-20 |
| MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma Bendamustine, Rituximab - Lymphoma, Indolent Non-hodgkin Lymphoma | Phase 2 | Not yet recruiting | Fox Chase Cancer Center | 24 | 2025-06-01 | 2025-01-06 |
| Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma Obinutuzumab, Glofitamab, Pirtobrutinib - Mantle Cell Lymphoma | Phase 2 | Recruiting | University of California, San Francisco | 30 | 2024-06-11 | 2026-10-01 |
| ImmuneSense™ IBD Study Inflammatory Bowel Diseases | Terminated | Adaptive Biotechnologies | 484 | 2022-10-31 | 2023-10-05 | |
| Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy ClonoSEQ - Follicular Lymphoma, Diffuse Large B Cell Lymphoma | Recruiting | Adaptive Biotechnologies | 300 | 2022-06-01 | 2024-08-22 | |
| Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant Autologous Stem Cell Transplant, Immunomodulatory Agent, Proteasome Inhibitor - Multiple Myeloma | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 69 | 2022-04-20 | 2026-03-02 | |
| ImmuneSense™ COVID-19 Cross-Reactivity Study Coronavirus Disease, SARS-CoV-2 Infection | Withdrawn | Adaptive Biotechnologies | 2021-12-15 | 2023-07-27 | ||
| ImmuneSense COVID-19 Variant Study T-Detect COVID test - Covid19 | Completed | Adaptive Biotechnologies | 203 | 2021-10-12 | 2022-12-07 | |
| The clonoSEQ® Watch Registry clonoSEQ Assay - Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia | Terminated | Adaptive Biotechnologies | 465 | 2020-10-13 | 2024-08-01 | |
| ImmuneSense™ COVID-19 Study T-Detect™ SARS-CoV-2 Assay - Coronavirus Disease (COVID-19), SARS-CoV-2 Infection | Completed | Adaptive Biotechnologies | 180 | 2020-10-09 | 2022-04-15 | |
| ImmuneSense Lyme Study T-Detect Lyme - Lyme Disease | Completed | Adaptive Biotechnologies | 893 | 2020-07-09 | 2022-04-15 | |
| Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax Venetoclax monotherapy, Venetoclax with anti CD20 monoclonal antibody - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 81 | 2020-05-13 | 2026-07-10 |
| ImmuneRACE - Immune Response Action to COVID-19 Events Covid19 | Completed | Adaptive Biotechnologies | 808 | 2020-04-24 | 2022-02-16 | |
| Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) Nivolumab, Nivolumab plus Ipilimumab - Bladder Cancer, Melanoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 81 | 2015-09-14 | 2025-07-22 |
COVID-19 (4) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Multiple Myeloma (2) · Neoplasm, Residual (2) · Colitis, Ulcerative (1) · Coronavirus Infections (1) · Crohn Disease (1) · Inflammatory Bowel Diseases (1) · Lyme Disease (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1)
Adjuvants, Immunologic (1) · Bendamustine Hydrochloride (1) · CD3 Complex (1) · Ipilimumab (1) · Nivolumab (1) · Proteasome Inhibitors (1) · Rituximab (1) · Sulfasalazine (1) · glofitamab (1) · obinutuzumab (1) · pirtobrutinib (1) · venetoclax (1)
United States (13)
Heidi Simmons, PhD (2) · Namita Singh, MD (2) · Darcy Gill (1) · Darcy Gill, PhD (1) · Doris Hansen, MD (1) · Madhav Seshadri, MD (1) · Marcus Messmer (1) · Meghan Thompson, MD (1) · Samuel Funt, MD (1)